$BRO

Citi upgraded Flutter (FLUT) to Buy with a $91 target. Cantor upgraded Humana (HUM) to Overweight with a $460 target. TD Cowen upgraded Marvell (MRVL) to Buy with a $350 target. Evercore upgraded NetApp (NTAP) to Outperform with a $300 target. Citi upgraded XPO (XPO) to Buy with a $224 target. UBS downgraded AppFolio (APPF) to Neutral with a $220 target. William Blair downgraded Option Care Health (OPCH) after its acquisition by CD&R and McKesson (MCK).

Oppenheimer initiated coverage of property & casualty insurance brokers, rating Brown & Brown (BRO) Outperform and Arthur J. Gallagher (AJG) Sector Perform. The firm expects BRO's organic growth to improve, driven by the Accession acquisition, while noting durable growth prospects for brokerages. However, AJG's margin improvement is expected to stall due to integration and industry challenges.

Analysts made several rating changes: UBS upgraded Invesco (IVZ) to Buy with a $41 target, Raymond James initiated M&T Bank (MTB) as Outperform with a $250 target, Morgan Stanley upgraded Nexa Resources (NEXA) to Overweight, and others. KeyBanc upgraded Corteva (CTVA) to Overweight with a $17 target, Jefferies upgraded Ambiq Micro (AMBQ) to Buy with a $90 target, and Citi upgraded Flutter to Buy with a $91 target.

Oppenheimer initiated coverage on Brown & Brown (BRO) with an Outperform rating and $73 price target, citing potential upside. BRO shares are down 24% YTD, underperforming peers. Q2 2026 earnings missed estimates, but revenue grew 30.4% YoY. Analysts have mixed outlooks on BRO's future performance.

Ryan Specialty (private) beat estimates but stock fell 14.5% to $37.69. Brown & Brown (BRO) reported $1.68B revenue, up 30.4% YoY, missing estimates, stock down 14% to $59.95. Baldwin Insurance (BWIN) reported $492.9M revenue, up 30.1% YoY, in line with estimates, stock up 19% to $31.77. Marsh (MRSH) reported $7.40B revenue, up 6.2% YoY, beating estimates, stock down 6.6% to $170.06.

BMO Capital lowered its price target for Brown & Brown from $74 to $65 while maintaining a Market Perform rating. The company's stock closed at $60.90 on September 30, 2026, with a 5-day change of +0.50% and a 1st Jan change of -1.30%.

Goldman Sachs reduced its price target for Brown & Brown from $73 to $68, maintaining a neutral rating. The company's stock closed at $60.90, up 0.50% for the day but down 1.30% for the week and 23.59% year-to-date.

Financial sector stocks fell Tuesday, led by Charles Schwab (down 5.5%), Allstate (5.0%), and Raymond James (4.5%). Major banks also declined, with Morgan Stanley (3.5%), Bank of America (3.4%), and JPMorgan Chase (3.0%) among the fallers. The drop came as investors rotated capital into tech stocks, particularly AI-related ones, according to Investing.com.

Ryan Specialty beat estimates but fell 11.1% to $39.20. Brown & Brown (BRO) reported $1.68B revenue, up 30.4% YoY, missing estimates by 2.5%, and dropped 3.4% to $67.32. Arthur J. Gallagher (AJG) reported $4.00B revenue, up 24.3% YoY, missing estimates by 0.5%, and fell 3.3% to $248.05. Marsh (MRSH) reported $7.40B revenue, up 6.2% YoY, beating estimates by 1.8%, and dropped 1.2% to $179.91.

Brown & Brown (BRO) shares fell 27.1% in the past year, underperforming the industry. Factors include soft organic growth, elevated costs, and acquisition debt. Analysts see a 12.2% upside to $76.69. The company projects 2026 EPS growth of 5.6% and revenue growth of 19.2%. Competitors AON, AJG, and WTW also declined. BRO trades at a discount with a forward P/E of 14.12x.